Skip to content

Study · Randomized controlled trial · n = 107 · 2017

3 results

Intranasal Oxytocin to Prevent Posttraumatic Stress Disorder Symptoms: A Randomized Controlled Trial in Emergency Department Patients.

van Zuiden M, Frijling JL, Nawijn L, Koch SBJ, Goslings JC, Luitse JS, Biesheuvel TH, Honig A, Veltman DJ, Olff M

Biological psychiatry8 Dec 2016Cited by 113 (Europe PMC)

PMID28087128 (opens in a new tab)DOI10.1016/j.biopsych.2016.11.012 (opens in a new tab)PepBankPUB-28087128
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In emergency department patients with acute distress, intranasal oxytocin did not significantly change the CAPS total score at 1.5 months posttrauma compared with placebo.

    In plain wordsIn emergency patients with acute distress, nasal oxytocin did not lower PTSD symptom scores at 1.5 months more than placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeCAPS total score at 1.5 months posttrauma
    Study

    n = 107

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    40 IU twice daily · intranasal · 8 daysAs given in this study (human).

    Source sentences

    Summary
    We did not observe a significant group difference in CAPS total score at 1.5 months posttrauma (primary outcome)
    1 context sentence
    Summary · context
    Adult emergency department patients with moderate to severe acute distress (n = 120; 85% accident victims) were randomized to intranasal oxytocin (8 days/40 IU twice daily) or placebo (8 days/10 puffs twice daily), initiated within 12 days posttrauma.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In emergency department patients with acute distress, intranasal oxytocin did not significantly change the CAPS total score across follow-up compared with placebo.

    In plain wordsIn emergency patients with acute distress, nasal oxytocin did not lower PTSD symptom scores across follow-up more than placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeCAPS total score across follow-up
    Study

    n = 107

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    40 IU twice daily · intranasal · 8 daysAs given in this study (human).

    Source sentences

    Summary
    We did not observe a significant group difference in CAPS total score at 1.5 months posttrauma (primary outcome) or across follow-up (secondary outcome).
    1 context sentence
    Summary · context
    Adult emergency department patients with moderate to severe acute distress (n = 120; 85% accident victims) were randomized to intranasal oxytocin (8 days/40 IU twice daily) or placebo (8 days/10 puffs twice daily), initiated within 12 days posttrauma.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In emergency department patients with high baseline CAPS scores, intranasal oxytocin gave significantly lower CAPS scores across follow-up than placebo.

    In plain wordsIn emergency patients with high early PTSD symptoms, nasal oxytocin led to lower symptom scores over follow-up than placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseCAPS scores across follow-up in participants with high baseline CAPS
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    40 IU twice daily · intranasal · 8 daysAs given in this study (human).

    Source sentences

    Summary
    Secondary analyses showed that participants with high baseline CAPS scores receiving oxytocin had significantly lower CAPS scores across follow-up than participants with high baseline CAPS scores receiving placebo.
    1 context sentence
    Summary · context
    Adult emergency department patients with moderate to severe acute distress (n = 120; 85% accident victims) were randomized to intranasal oxytocin (8 days/40 IU twice daily) or placebo (8 days/10 puffs twice daily), initiated within 12 days posttrauma.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT06945926

The Effect of Oxytocin Nasal Spray on Preventing Postoperative Delirium in Elderly Patients Undergoing Orthopedic Surgery

Zhejiang Universityn = 2271 Jun 2025 to 2 Jun 2026

Cervical Spinal Stenosis · Thoracic Spinal Stenosis · Lumbar Spinal Stenosis · Rotator Cuff Injury · Femoral Head Necrosis · Spinal Trauma · Knee Joint Injury

Trial pageClinicalTrials.govUpdated 20 Aug 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.